Armata Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Financial amounts below are in millions of dollars unless stated otherwise. Armata is a clinical-stage biotechnology company developing bacteriophage therapies for difficult-to-treat and antibiotic-resistant bacterial infections; it reported grant revenue, not product sales.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Grant revenue | $0.966 | $0.796 |
| Research and development expense | $8.016 | $9.604 |
| General and administrative expense | $3.178 | $2.538 |
| Operating loss | $(10.228) | $(11.346) |
| Interest expense | $(1.820) | — |
| Loss from change in fair value of convertible debt | $(13.025) | $(3.162) |
| Net loss | $(25.021) | $(14.490) |
| Net loss per share, basic and diluted | $(0.69) | $(0.40) |
| Net cash used in operating activities | $(10.584) | $(17.570) |
Cash was $37.860 million and restricted cash was $5.480 million at quarter-end. The company reported total assets of $120.356 million, current liabilities of $110.045 million, and a stockholders’ deficit of $56.510 million. Current assets were $41.717 million, implying a $68.328 million working-capital deficit.
Debt carrying values totaled approximately $132.0 million: $71.658 million of convertible debt and $60.378 million of term debt. The company’s new $35 million Innoviva loan bears 14% annual interest, is secured by substantially all company and subsidiary-guarantor assets, and matures June 4, 2025. The existing $25 million term loan also bears 14% and matures January 10, 2025. Both term loans’ principal and accrued interest are payable at maturity. The convertible loan is also due in January 2025, subject to conversion and repayment provisions.
No product gross margin or operating margin is presented. Grant revenue primarily reflects MTEC reimbursement of AP-SA02 program costs.
Material changes versus prior period
- Net loss increased 72.7%, primarily reflecting a $13.0 million noncash fair-value loss on convertible debt, compared with $3.2 million in Q1 2023, and new interest expense. Operating loss improved by $1.1 million.
- Research and development expense fell 16.5%, mainly because of lower clinical-trial and personnel costs, partly offset by higher facilities and overhead costs. Management cited a clinical research organization credit related to AP-SA02 costs. G&A expense rose 25.2%, primarily from higher legal, accounting, consulting, and facility costs.
- Operating cash use decreased to $10.6 million from $17.6 million. Financing provided $34.9 million, primarily from the new $35 million term loan; cash and restricted cash increased by $24.1 million during the quarter.
- Convertible debt’s carrying value rose from $58.6 million at year-end to $71.7 million, reflecting the fair-value remeasurement.
Outlook, programs, and risks
- Going concern: Management states that $37.9 million of cash at March 31, 2024 is insufficient to fund operations for the next 12 months from issuance of the financial statements. The filing says substantial doubt exists about the company’s ability to continue as a going concern. Plans for additional equity, debt, collaborations, licenses, grants, or other funding are not within the company’s control and are not considered probable of occurring.
- Clinical outlook: The AP-PA02 Phase 2 Tailwind trial in non-cystic fibrosis bronchiectasis was approximately 70% enrolled. Armata aims to define dose and treatment duration, with a definitive Phase 3 trial planned for 2025, subject to results and funding. The AP-SA02 diSArm bacteremia study was over 50% enrolled; the company is pursuing a definitive efficacy trial in 2025. These are plans, not assured milestones.
- Development risks: The company expects continued substantial losses and does not expect product revenue until a candidate is developed and receives marketing approval. Inability to obtain financing could force delays, reductions, or termination of programs or operations. Equity or convertible financing could dilute shareholders; collaboration or licensing deals could require relinquishing valuable rights.
- Debt and dilution: Loans from Innoviva, the company’s principal stockholder and a related party, carry 14% stated interest and are secured by substantially all assets. The convertible loan has a 15% discount feature in a qualifying financing and other conversion provisions. As of March 31, 2024, 21.7 million shares were issuable upon conversion and total shares reserved for future issuance were 48.6 million, versus 36.1 million shares outstanding.
- Other commitments: The company disclosed long-term facility leases and approximately $3.0 million of expected additional construction and improvement expenses by mid-2024. The MTEC award supports AP-SA02 and runs through October 30, 2024; commercialization or licensing of funded intellectual property may trigger payments to MTEC. The Cystic Fibrosis Foundation award includes development and commercialization-related conditions.
- The company reported no material change to the risk factors in its 2023 Form 10-K, no material legal proceeding, and no off-balance-sheet arrangements. Management stated that disclosure controls were effective as of March 31, 2024.
Investor verification points
- Confirm cash runway, spending plans, and whether additional financing has been secured; the filing explicitly identifies a going-concern uncertainty.
- Review the full Innoviva loan and convertible-loan documents, including maturity payments, collateral, covenants, conversion terms, and related-party implications.
- Track enrollment, data, regulatory interactions, funding, and timing for the AP-PA02 Tailwind and AP-SA02 diSArm programs and proposed 2025 studies.
- Assess the potential share dilution from conversion rights, warrants, options, and other reserved shares.
- Verify remaining facility construction costs and the timing and terms of MTEC and CFF obligations or potential future payments.